Tema Oncology ETF (NASDAQ:CANC) Short Interest Up 108.9% in August

Tema Oncology ETF (NASDAQ:CANC) was the target of a significant growth in short interest in August. As of August 31st, there was short interest totaling 22,352 shares, a growth of 108.9% from the August 15th total of 10,698 shares. Based on an average daily trading volume, of 22,950 shares, the days-to-cover ratio is presently 1.0 days. Currently, 0.5% of the company’s stock are sold short.

Tema Oncology ETF Price Performance

Shares of NASDAQ CANC traded down $0.50 during mid-day trading on Tuesday, reaching $41.57. 64,471 shares of the company’s stock were exchanged, compared to its average volume of 31,488. The firm has a market capitalization of $207.81 million, a price-to-earnings ratio of 20.39 and a beta of 0.69. Tema Oncology ETF has a 52 week low of $26.62 and a 52 week high of $47.00. The firm has a 50-day moving average price of $42.46 and a two-hundred day moving average price of $39.37.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Tema Oncology ETF stock. Roxbury Financial LLC bought a new position in shares of Tema Oncology ETF (NASDAQ:CANC) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 924 shares of the company’s stock, valued at approximately $34,000.

About Tema Oncology ETF

The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.